

FOR IMMEDIATE RELEASE

**Lee's Pharm wins the  
Technological Achievement Award in the  
2012 Hong Kong Awards for Industries**



**Hong Kong, Aug 30, 2012**—Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group") today is proud to announce that it has won the Technological Achievement Award in the 2012 Hong Kong Awards for Industries ("the HKAI Awards") organized by the Hong Kong Science and Technology Parks Corporation.

The HKAI, championed by the Government of HKSAR, evaluates and rewards annually the outstanding achievements of Hong Kong enterprises in pursuit of high technology advancement and high value-added endeavor. It is one of the most highly regarded honors in Hong Kong for technology-based enterprises. According to its objective, the "HKAI Awards, recognize excellence in technology and intellectual property as well as its contribution to Hong Kong."

The accolade honors Lee's Pharm's effort represented by its innovative product, namely Anfibatide, which is a first-in-class anti-platelet drug that Lee's has discovered and developed from bench to bedside. Dr. Benjamin Li, the CEO of the Group, received the Award on behalf of Lee's Pharm at the Awards Presentation Ceremony-cum-Gala Dinner held on the 27<sup>th</sup> August 2012 at the Convention Hall of Hong Kong Exhibition Centre. "We are extremely delighted and proud to receive this distinguished recognition for our effort in technology innovation. We will continue to dedicate ourselves on new drug discovery and development to address unmet medical needs."

**About Anfibatide**

Anfibatide ~ Antiplatelet Thrombolysin for injection, is a new molecular entity discovered and developed by the Group from bench to bedside. Anfibatide is a promising new GpIb-IV-V complex antagonist, exhibiting strong anti-platelet effects, excellent reversibility, and low bleeding tendency in human study. It represents a novel therapeutic mechanism and may advance the treatment of acute coronary syndrome and percutaneous coronary intervention. The successful development of this technology could result in a new paradigm for treatment of acute coronary syndrome. The Group has obtained patent in US and China.